血管性认知障碍痴呆的高级神经影像生物标志物指南与临床影响
本文围绕血管性认知障碍和痴呆的神经影像标志物,整合STRIVE-2影像术语与VasCog-2临床框架,综述动脉自旋标记、DTI及PSMD、定量磁敏感成像等高级MRI技术。重点整理已用于临床决策的定量阈值与抗淀粉样蛋白治疗相关的微出血、皮层浅表铁沉积标准,并讨论研究级与常规工作流的差距。
要点
- 报告脑小血管病时建议采用STRIVE-2影像术语以统一描述
- 评估抗淀粉样蛋白治疗资格需重点报告微出血和皮层浅表铁沉积
- PSMD已有验证参考范围并开始支持脑白质微结构定量判断
核心结论
- 神经影像是检测、表型分型和纵向监测血管性认知障碍和痴呆的核心手段
- 定量影像正在进入临床部署,放射科医生需结合模式识别与定量特征判读
- 定量VCID影像成为正式法规级生物标志物前仍需解决标准化、可重复性和外部验证问题
研究设计与样本
- 本文为神经放射学导向的综述,整合STRIVE-2影像术语与VasCog-2临床框架
- 纳入动脉自旋标记、弥散张量成像及PSMD、定量磁敏感成像、血管构筑成像和静息态功能MRI等技术
- 重点汇总已用于决策的操作性定量阈值、自动化分割与结构化报告进展
关键影像表现/征象
- 脑小血管病影像表现描述应遵循STRIVE-2影像词汇
- 脑白质高信号纵向进展与痴呆风险相关,可用于纵向监测
- 微出血和皮层浅表铁沉积是与抗淀粉样蛋白治疗资格相关的关键影像征象
- PSMD反映脑白质骨架化平均弥散率增宽,可从DTI获得并用于微结构量化
诊断标准与关键数值
- Staals总分用于整合脑小血管病影像负荷评分
- 微出血和皮层浅表铁沉积标准已用于判断抗淀粉样蛋白治疗资格
- PSMD已建立经过验证的参考范围并开始支持临床决策
- 脑白质高信号纵向进展可作为与痴呆风险相关的定量指标
- 动脉自旋标记、DTI、定量磁敏感成像、血管构筑成像及静息态功能MRI为本文综述的主要定量技术
临床应用与阅片要点
- 日常报告脑小血管病相关征象时应采用STRIVE-2术语以规范描述
- 阅片时需按抗淀粉样蛋白治疗评估要求单独核查微出血和皮层浅表铁沉积
- 自动化分割和结构化报告正在进入临床应用,可辅助放射科医生进行定量定性结合判读
局限性
- 研究级采集与常规临床工作流之间仍存在明显差距
- 定量影像的标准化、可重复性和外部验证仍是尚未满足的前提条件
- 本文为综述,未提供新的原始研究数据或前瞻性验证结果
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Vascular cognitive impairment and dementia (VCID) is a leading modifiable contributor to dementia, accounting for an estimated 27-33% of attributable dementia cases. Neuroimaging is central to detection, phenotyping, and longitudinal monitoring. This neuroradiology-focused review integrates the STRIVE-2 imaging lexicon with the VasCog-2 clinical framework and reviews the advanced MRI techniques most pertinent to VCID, spanning clinically established to emerging research approaches: arterial spin labelling, diffusion tensor imaging including peak width of skeletonised mean diffusivity (PSMD), quantitative susceptibility mapping, vessel architecture imaging, and resting-state functional MRI. Unlike previous reviews, we consolidate operational quantitative thresholds already informing decisions (the Staals total small-vessel-disease score, longitudinal white matter hyperintensity progression linked to dementia risk, microbleed and cortical superficial siderosis (cSS) criteria for anti-amyloid therapy eligibility, and validated PSMD reference ranges) and we critically address gaps between research-grade acquisitions and routine clinical workflows. Automated segmentation and structured reporting are transitioning into deployment, expanding the radiologist's role to combine pattern recognition with quantitative characterisation. We outline current limitations of standardisation, reproducibility, and external validation that remain prerequisites before quantitative VCID imaging achieves formal regulatory biomarker qualification.
引用
- Ojeda-Esparza, Botta, Fitsiori, et al. Advanced neuroimaging of vascular cognitive impairment and dementia: biomarkers, guidelines, and clinical impact. Br J Radiol. 2026. PMID: 42568133. doi:10.1093/bjr/tqag182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。